Commercial debut AC5 Advanced Wound System is Arch Therapeutics' first commercial product and is actively being showcased at major wound care events, signaling immediate sales opportunities with wound care centers, hospitals, and surgical facilities seeking novel hemostasis and wound management solutions.

Regulatory market Arch has regulatory authorization to market AC5 in the United States and Europe, providing a regulatory-ready pathway for pursuing clinician adoption, distributor agreements, and direct sales channels across these regions.

Clinical momentum Past and ongoing clinical and multi-site studies for AC5 and related devices enhance value propositions around efficacy in challenging wounds, supporting conversations with payors, hospitals, and surgeons about improved outcomes and potential cost savings.

Strategic partnerships Existing distribution collaboration with Centurion Therapeutics and past financing/board additions indicate a network-oriented go-to-market approach, suggesting opportunities to expand in tissue banks, burn centers, and trauma care networks through co-marketing and mutual referrals.

Growth funding Recent bridge financing and ongoing development of additional AC5 variants point to a growth trajectory that can unlock larger procurement opportunities within mid-to-large healthcare systems and specialty surgical services seeking innovative biosurgical solutions.